Sosipatros A Boikos
Overview
Explore the profile of Sosipatros A Boikos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smith S, Sweeney K, Evans M, Angara K, Reynolds C, Price B, et al.
Mod Pathol
. 2025 Feb;
38(4):100737.
PMID: 39956270
Dermatofibrosarcoma protuberans (DFSP) is a locally aggressive cutaneous neoplasm driven by PDGFB or, rarely, PDGFD gene fusions. In some cases, DFSP progresses to a fibrosarcomatous form with metastatic potential, which...
2.
Shan D, Noland M, Diaz-Perez J, Boikos S, Mochel M
J Cutan Pathol
. 2024 Nov;
52(2):104-107.
PMID: 39603691
While most forms of alopecia neoplastica are attributable to cutaneous metastases from visceral primary malignancies, rarely a diffuse primary skin cancer may present as alopecia. Herein, we present a case...
3.
Floros K, Fairchild Jr C, Li J, Zhang K, Roberts J, Kurupi R, et al.
Res Sq
. 2024 Jun;
PMID: 38883782
Synovial Sarcoma (SS) is driven by the SS18::SSX fusion oncoprotein and is ultimately refractory to therapeutic approaches. SS18::SSX alters ATP-dependent chromatin remodeling BAF (mammalian SWI/SNF) complexes, leading to the degradation...
4.
Floros K, Fairchild C, Li J, Zhang K, Roberts J, Kurupi R, et al.
bioRxiv
. 2024 May;
PMID: 38712286
Synovial Sarcoma (SS) is driven by the SS18::SSX fusion oncoprotein. and is ultimately refractory to therapeutic approaches. SS18::SSX alters ATP-dependent chromatin remodeling BAF (mammalian SWI/SNF) complexes, leading to the degradation...
5.
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
Ingham M, Allred J, Chen L, Das B, Kochupurakkal B, Gano K, et al.
J Clin Oncol
. 2023 Jul;
41(25):4154-4163.
PMID: 37467452
Purpose: Uterine leiomyosarcoma (uLMS) is an aggressive subtype of soft-tissue sarcoma with frequent metastatic relapse after curative surgery. Chemotherapy provides limited benefit for advanced disease. Multiomics profiling studies have identified...
6.
Hiemenz M, Kaur J, Kuang Z, Huang R, Harries L, Metzger D, et al.
Genes Chromosomes Cancer
. 2023 Mar;
62(8):460-470.
PMID: 36862145
Gene fusions involving EWSR1 or FUS as the 5' partner have been reported in a diverse array of sarcomas. Here, we characterize the histopathology and genomics of six tumors harboring...
7.
Jacob S, Turner T, Cai J, Floros K, Yu A, Coon C, et al.
PNAS Nexus
. 2023 Jan;
1(5):pgac232.
PMID: 36712364
Triple negative breast cancer (TNBC) accounts for over 30% of all breast cancer (BC)-related deaths, despite accounting for only 10% to 15% of total BC cases. Targeted therapy development has...
8.
Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1
Kurupi R, Floros K, Jacob S, Chawla A, Cai J, Hu B, et al.
Cancer Res Commun
. 2022 Dec;
2(9):1061-1074.
PMID: 36506869
Preclinical and clinical studies have evidenced that effective targeted therapy treatment against receptor tyrosine kinases (RTKs) in different solid tumor paradigms is predicated on simultaneous inhibition of both the PI3K...
9.
Cai J, Jacob S, Kurupi R, Dalton K, Coon C, Greninger P, et al.
Cell Rep
. 2022 Jul;
40(4):111095.
PMID: 35905710
Reoccurring/high-risk neuroblastoma (NB) tumors have the enrichment of non-RAS/RAF mutations along the mitogen-activated protein kinase (MAPK) signaling pathway, suggesting that activation of MEK/ERK is critical for their survival. However, based...
10.
Floros K, Chawla A, Johnson-Berro M, Khatri R, Stamatouli A, Boikos S, et al.
Cell Stress
. 2022 Feb;
6(2):21-29.
PMID: 35174317
Ferroptosis is an iron-dependent, oxidative form of cell death that is countered mainly by glutathione peroxidase 4 (GPX4) and the production of glutathione (GSH), which is formed from cysteine. The...